2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 806

STAT1 Activation Promotes TLR8 Overexpression and Facilitates Mirokine Signaling Via Exosomes Containing a Mir-21 Endogenous Ligand: A Novel Innate Inflammatory Pathway in Systemic Lupus Erythematosus
Abstract Number: 1936

STAT3-Regulated Gene Expression in Circulating CD4+ T Cells Discriminates RA Patients Independently of Clinical Parameters in Early Arthritis: A Validation Study
Abstract Number: 2892

Statin Treatment in Patients with Ankylosing Spondylitis
Abstract Number: 601

Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis
Abstract Number: 2717

Stf-083010, the Inhibitor of ER Stress Transducer IRE1, Suppresses Rheumatoid Synovitis
Abstract Number: 383

Stiffness Index Study in Ehler Danlos Syndrome
Abstract Number: 858

Stimulated Renal Glomerular Endothelial Cells Were Damaged By Fiber-like NETs Released By Neutrophils in ANCA-Associated Vasculitis
Abstract Number: 2826

Stimulation of Autophagy Reduces Misfolded HLA-B27 in a Rat Model of Spondyloarthritis
Abstract Number: 2209

Stimulation of the Adenosine A2A Receptor (A2AR) Regulates the Expression of Netrin-1 (Ntn1) and Its Receptors (Unc5b, DCC) and Inhibits Wear Particle-Induced Inflammatory Osteolysis in a Model of Joint Prosthesis Loosening
Abstract Number: 1906

Stimulators of Soluble Guanylate Cyclase (sGC) Improve Wound Healing in the Tsk-1 Mouse Skin Fibrosis Mode
Abstract Number: 1905

Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies
Abstract Number: 3175

Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass
Abstract Number: 315

Structural Effects of Sprifermin in Knee Osteoarthritis: A Post-Hoc Analysis on Cartilage and Non-Cartilaginous Tissue Alterations
Abstract Number: 2747

Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy
Abstract Number: 2616

Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].